Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hunan Zhaotai Medical Group
Changsha, Hunan, Chinazhaotai.com.cn ↗
- Ownership
- Private
- Employees
- ~130
- Development stage
- Phase 1
01
Overview
The company has developed a novel CAR T-cell construct with a unique, patented co-stimulatory domain that produces stronger anti-cancer activity in the laboratory than existing second-generation CAR T-cells. Preliminary clinical data suggests an improved safety profile with fewer side effects than competing CAR T-cell treatments. Phase I trials have been conducted for various cancers, and results of the ENABLE trial in New Zealand were due to be published in 2023.
- Therapeutic areas
- Oncology
- Modalities
- CAR T-cell therapiesTIL therapyNatural Killer Cell Therapies
- Industry
- Biotech
02
Partnerships
Wellington Zhaotai Therapies (joint venture with Malaghan Institute of Medical Research)Dr. Reddy's Laboratories
Beyond the preview
Go deeper on Hunan Zhaotai Medical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hunan Zhaotai Medical Group.